Publications by authors named "Anabel B Sanchez-Spitman"
Article Synopsis
- - Tamoxifen is commonly used in breast cancer treatment, but how effective it is can vary significantly among patients, primarily due to differing levels of its active metabolite, endoxifen.
- - A genome-wide association study (GWAS) involving 608 women aimed to find genetic factors that influence endoxifen levels and patient survival outcomes, revealing multiple significant genetic variants.
- - The study found that certain genetic variants on chromosome 22, including those linked to the CYP2D6 gene, are strongly associated with both endoxifen concentration and relapse-free survival in breast cancer patients on tamoxifen.
Purpose: Tamoxifen is part of endocrine therapy in breast cancer treatment. Studies have indicated the use of endoxifen concentrations, tamoxifen active metabolite, to guide tamoxifen efficacy. Three endoxifen thresholds have been suggested (5.
View Article and Find Full Text PDFAim: CYP2D6*2 is considered fully active, but it has been suggested that it only happens in the presence of rs5758550. This study aims to elucidate the impact of this enhancer.
Materials & Methods: DNA and blood samples from women enrolled in the CYPTAM study (NTR1509) were analyzed.